EMAIL THIS PAGE TO A FRIEND

The Journal of clinical endocrinology and metabolism

Loss of CPSF2 expression is associated with increased thyroid cancer cellular invasion and cancer stem cell population, and more aggressive disease.


PMID 24654752

Abstract

Identification of molecular factors that promote thyroid cancer progression have important clinical implications for therapy and prognostication in patients with papillary thyroid cancer (PTC). The aim of this study was to validate and determine the function of dysregulated genes that were associated increased mortality in patients with PTC. Experiemental Design: We selected the cleavage and polyadenylation specificity factor subunit 2 (CPSF2) gene from the top 5 significantly dysregulated genes associated with PTC-associated mortality from our previous study. We used 86 PTC samples enriched for aggressive disease (recurrence and mortality) by quantitative RT-PCR (qRT-PCR). In vitro functional studies of the validated gene were performed. Decreased CPSF2 gene expression was associated with shorter disease-free survival (P = .03), large tumor size (T3 and T4) (P = .03), tumor recurrence (P < .01), and mortality (P < .01), independent of BRAF V600E mutation status. CPSF2 knockdown increased cellular invasion by 1.8- to 3.2-fold (P < .01) and increased markers of thyroid cancer stem cells (CD44 and CD133 expression). Immunohistochemistry showed an inverse correlation between CD44 protein expression in PTC samples and CPSF2 expression. Decreased CPSF2 expression is associated with increased cellular invasion and cancer stem cell population, and more aggressive disease in PTC.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

GW22755 Anti-CD44 antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
SAB1405590
Anti-CD44 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA005785
Anti-CD44 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4300691
Anti-CD44 antibody produced in rabbit, affinity isolated antibody
SAB4300621
Anti-CDH2 antibody produced in rabbit, affinity isolated antibody
SAB2107606
Anti-PROM1 antibody produced in rabbit, affinity isolated antibody, lyophilized powder
C7923 Monoclonal Anti-CD44 antibody produced in mouse, clone A3D8, purified immunoglobulin, buffered aqueous solution
SAB1402714
Monoclonal Anti-CD44 antibody produced in mouse, clone 1E1, purified immunoglobulin, buffered aqueous solution
SAB4700179 Monoclonal Anti-CD44 antibody produced in mouse, clone MEM-85, purified immunoglobulin, buffered aqueous solution
SAB4700184 Monoclonal Anti-CD44 antibody produced in mouse, clone MEM-263, purified immunoglobulin, buffered aqueous solution
SAB4700188 Monoclonal Anti-CD44 antibody produced in rat, clone IM7, purified immunoglobulin, buffered aqueous solution
WH0001000M1
Monoclonal Anti-CDH2 antibody produced in mouse, clone 5C8, purified immunoglobulin, buffered aqueous solution
C2542 Monoclonal Anti-N-Cadherin antibody produced in mouse, clone GC-4, ascites fluid